| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Belite Bio, Inc (BLTE) has 2 insiders with recent SEC Form 4 filings, including 0 buys and 29 sells. BLTE is classified in the Biotechnology industry within the Healthcare sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 25.0K | $4.03M | - | |
| Other | 766 | $123.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 10,000 | $140.57 | $1,405,729.41 | -4.2% | - | - | |
| May 6, 2026 | Mata Nathan L. | Chief Scientific Officer | Sell | 1,000 | $153.84 | $153,838.71 | -13.7% | - | - | |
| May 1, 2026 | Mata Nathan L. | Chief Scientific Officer | Sell | 1,000 | $155.78 | $155,777.84 | -3.1% | - | - | |
| Apr 20, 2026 | Mata Nathan L. | Chief Scientific Officer | Sell | 1,000 | $163.59 | $163,594.55 | -1.1% | -8.9% | - |